AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in